Table 4.
Input used for the cost-effectiveness analysis based on the 3-state Markov model (N=198).
| Input | Intervention group (n=98) | Comparator group (n=100) | |||
| Transition probabilities, % |
|
|
|||
|
|
Incidence | 34 | 36 | ||
|
|
Recovery | 66 | 64 | ||
| Relative risk (mortality) |
|
|
|||
|
|
Baseline disease stage | 1.005 | 1.005 | ||
|
|
Deteriorated disease stage | 1.005 | 1.005 | ||
| Utility after intervention |
|
|
|||
|
|
Baseline disease stage | 0.56 | 0.45 | ||
|
|
Deteriorated disease stage | 0.3 | 0.33 | ||
| Costs, € ($)a |
|
|
|||
|
|
One-off cost per patient (intervention) | 1268.89 (1484.60) | N/Ab | ||
|
|
Recurring cost per patient/year (intervention) | 230.40 (269.57) | N/A | ||
|
|
Health care cost—baseline disease stage | 5664.89 (6627.92) | 5198.62 (6082.39) | ||
|
|
Health care cost—deteriorated disease stage | 4502.89 (5268.38) | 5221.69 (6109.38) | ||
|
|
Societal cost—baseline disease stage | 5953.15 (6965.19) | 5259.14 (6153.19) | ||
|
|
Societal cost—deteriorated disease stage | 4791.15 (5605.65) | 5282.21 (6180.19) | ||
aAn approximate exchange rate of €1 to US $1.17 was applicable at the time of publication.
bN/A: not applicable.